Biovest International, Inc. CEO Carlos F. Santos, Ph.D. To Present At The Phacilitate Immunotherapy Forum
1/27/2014 9:30:09 AM
MINNEAPOLIS & TAMPA, Fla.--(BUSINESS WIRE)--Biovest International, Inc. (“Biovest”), a leader and a pioneer in the development of personalized cancer immunotherapies, today announced that Biovest’s Chief Executive Officer, Carlos F. Santos, Ph.D., will deliver the keynote presentation at the Phacilitate Immunotherapy Forum (part of Phacilitate’s Washington Bioleaders 2014 Conference) taking place at the Grand Hyatt Hotel on January 27-29, 2014 in Washington, D.C. The keynote presentation on Monday, January 27, 2014 is titled “The Integration of Clinical Bioinformatics, Automated Cell Culture, and Automated Manufacturing for the Rapid Development of Personalized Lymphoma Vaccines”, and Dr. Santos will be a panelist for the corresponding discussion session. Dr. Santos will serve as the chair and moderator of the Tuesday, January 28, 2014 morning plenary session of the Immunotherapy Forum. He will also make a presentation titled "Case Study: Making the Personal Affordable: Efficient Manufacture of Autologous Cancer Immunotherapies”, and will act as an informal panelist for the panel discussion to follow. On the final day of the Conference, January 29, 2014, Dr. Santos will present "Case Studies of Personalized Immunotherapies in Development – Examining Trial Designs and Biomarker R&D Strategies – Case Study 3”.
“This forum provides us an excellent opportunity to advance personalized immunotherapy and interact with leaders in the fields of cancer vaccines, cell and gene therapy, and biologics manufacturing,” said Dr. Santos. “At Biovest, we have developed a highly personalized, tumor-matched cancer vaccine (BiovaxID; dasiprotimut-T) to fight non-Hodgkin’s lymphoma. As part of our efforts in bringing this vaccine to market, we have also pioneered highly automated systems for biomanufacturing of personalized medicines. We believe these advances, together with the clinical informatics and biomarker data which accompanies each of our vaccines, will ultimately make cancer vaccines much more accessible for patients diagnosed with non-Hodgkin’s lymphoma.”
Robert E. Farrell, J.D., Biovest’s Chief Financial Officer, will be presenting at the Personalized Medicines World Conference of Silicon Valley on January 27-28, 2014. Mr. Farrell’s presentation, “Automated Systems for Personal-Scale Manufacture of Commercial Cancer Vaccines“, will take place on January 28, 2014 at 8:45 AM PST at the Computer History Museum in Mountain View, CA. Mr. Farrell stated, “both of these conferences will present substantial exposure for Biovest’s immunotherapy program and provide an exciting opportunity to network with the biotechnology, personalized medicine, active immunotherapy, and investment communities. They provide outstanding venues in which to display our pioneering advances in personalized cancer vaccines.”
About Biovest International, Inc.
Biovest International, Inc. develops autologous active immunotherapies (personalized cancer vaccines) to treat B-cell non-Hodgkin’s lymphomas, which are cancers of the immune system. The Company’s lead personalized cancer vaccine candidate, BiovaxID, has undergone three clinical trials conducted in collaboration with the U.S. National Cancer Institute (NCI) that have demonstrated BiovaxID’s ability to increase the duration of cancer remission following chemotherapy and to induce immune responses which correlate highly with long-term survival. Biovest is currently in the process of pursuing European marketing approval for BiovaxID.
For further information, please visit: http://www.biovest.com
Statements in this press release that are not strictly historical in nature constitute "forward-looking statements.” Such statements include, but are not limited to, statements about Biovest , its product candidate, BiovaxID™ and any other statements relating to products, product candidates, product development programs, the FDA, the EMA, or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as “proposed”, “proposes”, “seeking”, "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. In particular (and without limitation), statements regarding potential approval of a Marketing Authorization Application for BiovaxID by the European Commission, pre-filing meetings with the FDA or other jurisdictions and/or commercial plans reflect current expectations but are subject to inherent risks of delay in compilation and finalization of all components of the licensing application. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Biovest International, Inc.
David Moser, 813-864-2554 Ext 267
Help employers find you! Check out all the jobs and post your resume.